

Supplementary Information 2: Figures S1–S9

Figure legends

Fig. S1 Epithelial annotation evidence and donor composition

Marker-expression dot plot, cluster-to-state evidence and donor/state composition. Cell-weighted marker summaries are displays, not inferential tests. Donor-dominated uncertain clusters are flagged

Fig. S2 Complete donor-level primary-screen audit

Minimum P/FDR values, tested-gene counts and donor eligibility for all four modeled epithelial states. Zero genes passed the FDR threshold

Fig. S3 Six post-hoc candidate modules and selection steps

All six modules passing the recorded exploratory filter are shown, including Stem_progenitor_SB_M12. Stage-label-blind covariance construction is separated from later stage-aware, paired-FAP and leave-one-donor-out filters

Fig. S4 M02 gene composition, annotation overlap and leave-one-gene influence

The canonical 36 genes, descriptive categories, selection-affected gene contributions and overlap with epithelial-state annotation evidence. No g:Profiler term was significant after g:SCS correction. The figure spans two pages to maintain readable lettering

Fig. S5 GSE161277 patient-level results for all six candidate modules

Patient differences and six-module adjusted results in the three matched donors. M02 is not presented as independently supported

Fig. S6 Bulk cohort details, standardized sensitivity and cancer-only context

Platform-specific bulk effects and leave-one-accession-out summaries are separated from GSE132465 and TCGA cancer-only context panels. Sample-scoped arrays are not relabeled as patients

Fig. S7 Stool-RNA model degeneration and one-time test

Selected-feature counts, coefficient structure, number of unique predicted probabilities and frozen test AUCs. The test split was used once and retired; no direct 36-gene test was added


Fig. S8 Figshare feature mapping and endpoint non-estimability

The mapping path from 36 canonical genes to 33 available features is shown. The historical “29/36” name represented a minimum threshold, while all 33 mapped genes were averaged. The canonical 36-gene endpoint was not estimable


Fig. S9 Simulation-based spatial recoverability and region-registration feasibility



Pseudo-spot score recovery is labeled as simulation-based technical performance. Region-registration agreement was assessed without M02 values but lacked an independent pathologist gold standard. Only case4 passed. Its primary and most sensitivity scores were negative, whereas gene-z was effectively zero; the frozen description was method dependent. Patient-level spatial analysis was not estimable

A Marker evidence




B Largest donor fraction by epithelial state




A Minimum nominal P**B Minimum FDR****C Genes tested and donor counts**

Inside bars: normal; adenoma; cancer




A Six selected modules



B Selection quantities

Stage-aware and FAP-aware filters



State



Cycling



Stem_progenitor

Genes



100



200



300




Paired FAP effect



Stage effect

a Selection-affected gene contributions



Descriptive category

- receptor or signal transduction
- extracellular matrix or adhesion
- WNT linked or epithelial state
- glycosylation or metabolism
- transcriptional or nuclear regulation
- long noncoding or poorly characterized
- immune linked or contamination sensitive
- enzyme or protein processing
- membrane transport or cell surface
- other or poorly characterized


b Overlap with annotation evidence

Five recorded overlaps; module characterization is not independent of all state-label evidence


M02 gene	Evidence source	Label / cluster	Interpretive consequence
NKD1	cluster annotation	cluster 1	overlap disclosed; no exclusion from M02
APCDD1	cluster annotation	cluster 1	overlap disclosed; no exclusion from M02
NKD1	cluster annotation	cluster 8	overlap disclosed; no exclusion from M02
APCDD1	cluster annotation	cluster 8	overlap disclosed; no exclusion from M02
ASCL2	broad annotation evidence	Stem/progenitor	overlap disclosed; no exclusion from M02

No g:Profiler term reached adjusted $P < 0.05$ against the 1,000-gene Stem/progenitor construction background

A Six-module paired effects




B Donor-specific differences




A Leave-one-accession-out sensitivity

Only two accessions remain in each row



B Cancer-only context

Not evidence about adenoma onset




A Selected features

Non-intercept terms




B Unique test probabilities



C One-time test AUC


Frozen test set



A Canonical feature mapping


33 mapped; 3 absent; 36-gene endpoint not estimable

Canonical genes



B Reduced-coverage descriptions


Historical '29/36' label used all 33 mapped genes



Donor ● P1 ● P5


A Simulated score recovery

72 replicates; not patients




B Region-registration gate


No independent pathologist gold standard






C case4 descriptive directions

n=1 patient; no P value or CI



a

chronology/data flow only; arrows do not imply biological causation

b All epithelium**c Stem/progenitor****d**

Same four module-generating FAP donors; empirical tail fractions are not post-selection P values

Fig. S10 Selection chronology, random-gene-set reference and leave-one-donor-out audit

(a) Analysis chronology distinguishes the negative project-recorded screen, post-hoc module generation, candidate lock and later assessments. (b,c) M02 effects are overlaid on 10,000 expression- and variability-matched and 10,000 unmatched random 36-gene module distributions for all epithelium and Stem/progenitor profiles. (d) Four leave-one-donor-out means in each compartment. Tail fractions are descriptive and are not valid post-selection P values; all panels use the same four module-generating FAP donors.